Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/onc.2016.363 http://scihub22266oqcxt.onion/10.1038/onc.2016.363 C5393956!5393956!27748764     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Oncogene 2017 ; 36 (16): 2191-201 Nephropedia Template TP {{tp|p=27748764|t=2017. mTORC1 and mTORC2 in cancer and the tumor microenvironment |pdf=|usr=}}{{27748764}} gab.com Text mTORC1 and mTORC2 in cancer and the tumor microenvironment JO: Oncogene http://www.kidney.de/pget.php?&tw=1&pmid=27748764 #FOAvip The mammalian target of rapamycin (mTOR) is a crucial signaling node that integrates environmental cues to regulate cell survival, proliferation, and metabolism, and is often deregulated in human cancer. mTOR kinase acts in two functionally distinct complexes, mTOR complex 1 (mTORC1) and 2 (mTORC2), whose activities and substrate specificities are regulated by complex co-factors. Deregulation of this centralized signaling pathway has been associated with a variety of human diseases including diabetes, neurodegeneration, and cancer. While mTORC1 signaling has been extensively studied in cancer, recent discoveries indicate a subset of human cancers harboring amplifications in mTORC2-specific genes as the only actionable genomic alterations, suggesting a distinct role for mTORC2 in cancer as well. This review will summarize recent advances in dissecting the relative contributions of mTORC1 versus mTORC2 in cancer, their role in tumor-associated blood vessels and tumor immunity, and provide an update on mTOR inhibitors. Twit Text FOAVip mTORC1 and mTORC2 in cancer and the tumor microenvironment ????Oncogene http://www.kidney.de/pget.php?&tw=1&pmid=27748764 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27748764 #FOAvip English Wikipedia <ref>{{Cite pmid|27748764}}</ref> mTORC1 and mTORC2 in cancer and the tumor microenvironment #MMPMID27748764 Kim LC; Cook RS; Chen J Oncogene 2017[Apr]; 36 (16): 2191-201 PMID27748764show ga The mammalian target of rapamycin (mTOR) is a crucial signaling node that integrates environmental cues to regulate cell survival, proliferation, and metabolism, and is often deregulated in human cancer. mTOR kinase acts in two functionally distinct complexes, mTOR complex 1 (mTORC1) and 2 (mTORC2), whose activities and substrate specificities are regulated by complex co-factors. Deregulation of this centralized signaling pathway has been associated with a variety of human diseases including diabetes, neurodegeneration, and cancer. While mTORC1 signaling has been extensively studied in cancer, recent discoveries indicate a subset of human cancers harboring amplifications in mTORC2-specific genes as the only actionable genomic alterations, suggesting a distinct role for mTORC2 in cancer as well. This review will summarize recent advances in dissecting the relative contributions of mTORC1 versus mTORC2 in cancer, their role in tumor-associated blood vessels and tumor immunity, and provide an update on mTOR inhibitors. ämTORC1 and mTORC2 in cancer and the tumor microenvironment (epmc).pdf DeepDyve Pubget Overpricing